By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience has submitted a 510(k) application with the US Food and Drug Administration for its illumigene C. difficile molecular diagnostic test.

The illumigene C. difficile test detects and amplifies a pathogenic DNA region of all toxin-producing strains of Clostridium difficile. The test uses a stool sample and can provide results in less than an hour, said Meridian.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.